Product Code: IRTNTR7888
About colorectal cancer
Colorectal cancer refers to malignancies that originate in the rectum or the colon. It is also known as bowel cancer. Formation of adenocarcinomas is the most common feature of colorectal cancer. The cancer starts as a polyp in the inner wall of the colon or rectum. These polyps can be benign or malignant. Some of the risk factors that can cause colorectal cancer are lifestyle changes, old age, genetic disorders, family history, and inflammatory bowel disease. Some of the symptoms of colorectal cancer are blood in stool, decrease in appetite, constipation, weight loss, nausea, bloating, and pelvic pain. Colorectal cancer can be classified into four broad stages. Colorectal cancer can be treated using surgical, chemotherapeutic, biologic, and radiation therapies.
Technavio's analysts forecast the colorectal cancer therapeutics market in APAC to grow at a CAGR of 6.32% over the period 2014-2019.
Covered in this report
The report covers the current scenario and the growth prospects of the colorectal cancer therapeutics market in APAC for the period 2015-2019. To calculate the market size, the report considers revenue generated through the sales of various drugs used in the treatment of colorectal cancer. The colorectal cancer therapeutics market in APAC is segmented based on lines of chemotherapy: first-line chemotherapy and second-line chemotherapy.
Technavio's report, Colorectal Cancer Therapeutics Market in APAC 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers APAC; it also covers the landscape of the colorectal cancer therapeutics market in APAC and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key regions
Key vendors
- Amgen
- Bayer
- Bristol-Myers Squibb
- Chugai Pharmaceuticals
- Merck
- Sanofi
Other Prominent Vendors
- Accord Healthcare
- Advenchen Laboratories
- Aeterna Zentaris
- AstraZeneca
- AVEO Oncology
- Bavarian Nordic
- Biothera
- Boehringer Ingelheim
- Boston Biomedical
- Cancer Prevention Pharmaceuticals
- Celator Pharmaceuticals
- Daiichi Sankyo
- Debiopharm
- Eisai
- Eli Lilly
- EpicentRx
- GlaxoSmithKline
- Hutchison Medipharma
- Immodulon Therapeutics
- Immunomedics
- MacroGenics
- Merrimack Pharmaceuticals
- MolMed
- Mologen
- Morphotek
- Mylan
- Nektar Therapeutics
- Oncothyreon
- Otsuka Pharmaceutical
- PledPharma
- Precision Biologics
- PsiOxus Therapeutics
- Sun Pharmaceutical
- Symphogen
- Taiho
- Takeda
- Teva Pharmaceuticals
- ThromboGenics
- Xbiotech
- Yakult Honsha
Key market driver
- Increase in aging population
- For a full, detailed list, view our report
Key market challenge
- Unknown disease etiology
- For a full, detailed list, view our report
Key market trend
- Rise in public awareness
- For a full, detailed list, view our report
Key questions answered in this report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
Table of Contents
PART 01: Executive summary
PART 02: Scope of the report
- Market overview
- Top-vendor offerings
- Vectibix
PART 03: Product profiles
- Stivarga
- Erbitux
- Xeloda
- Avastin
- Zaltrap
PART 04: Market research methodology
- Research methodology
- Economic indicators
PART 05: Introduction
PART 06: Disease overview
- Understanding the disease
- High risk factors
- Signs and symptoms
- Pathophysiology
- Diagnosis
- Staging
- Biomarker testing
- Epidemiology
- Treatment
PART 07: Pipeline portfolio
- Information on pipeline candidates
PART 08: Market landscape
- Market overview
- Market size and forecast
- Colorectal cancer therapeutics market in Japan
- Colorectal cancer therapeutics market in China
- Five forces analysis
PART 09: Market segmentation by based on the type of molecules
- Small molecules
- Biologics
PART 10: Market segmentation by route of administration
PART 11: Market segmentation by lines of chemotherapy
- First-line chemotherapy
- Second-line chemotherapy
PART 12: Market drivers
PART 13: Impact of drivers
PART 14: Market challenges
PART 15: Impact of drivers and challenges
PART 16: Market trends
PART 17: Vendor landscape
- Competitive scenario
- Market share analysis 2014
- Other prominent vendors
- Amgen
PART 18: Key vendor analysis
- Bayer HealthCare
- Bristol-Myers Squibb
- Chugai Pharmaceutical
- Merck
- Sanofi
PART 19: Appendix
PART 20: Explore Technavio